LY341495 is primarily used in neuroscience research as a selective antagonist for group II metabotropic glutamate receptors (mGluR2 and mGluR3). It is widely applied in studies investigating the role of these receptors in various neurological and psychiatric conditions, such as anxiety, depression, schizophrenia, and cognitive disorders. By blocking these receptors, LY341495 helps researchers understand their function in synaptic transmission and neural circuitry. Additionally, it is utilized in preclinical studies to explore potential therapeutic targets for treating brain disorders. Its high selectivity and potency make it a valuable tool for dissecting the complex mechanisms of glutamate signaling in the central nervous system.